Skip to main content
Contact Us
Subscribe
E-Edition
30°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aldeyra Therapeu
(NQ:
ALDX
)
2.780
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
430
Open
2.780
Bid (Size)
2.750 (1)
Ask (Size)
2.820 (7)
Prev. Close
2.780
Today's Range
2.780 - 2.780
52wk Range
1.460 - 11.97
Shares Outstanding
58,576,350
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
March 05, 2024
Via
Benzinga
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
February 09, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Performance
YTD
-21.47%
-21.47%
1 Month
-19.19%
-19.19%
3 Month
-6.08%
-6.08%
6 Month
-56.97%
-56.97%
1 Year
-62.63%
-62.63%
More News
Read More
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
January 04, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study
December 19, 2023
Via
Benzinga
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
December 19, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
December 18, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
3 Stocks at the Forefront of Personalized Medicine Trend
December 05, 2023
Via
InvestorPlace
FDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional Study
November 28, 2023
Via
Benzinga
Exposures
Product Safety
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
November 27, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 01, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 01, 2023
Via
Benzinga
What's Going On With Aldeyra Therapeutics Stock?
November 01, 2023
Via
Benzinga
Aldeyra Therapeutics Inc. (NASDAQ: ALDX) is One of Wednesday Morning’s Most Active Stocks
November 01, 2023
Via
Investor Brand Network
Why Are Stocks Up Today?
November 01, 2023
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
November 01, 2023
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 01, 2023
Via
Benzinga
Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap
November 01, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
NASDAQ:ALDX Long Term Investor Alert: Investigation over Potential Wrongdoing at Aldeyra Therapeutics, Inc.
October 17, 2023
Via
SBWire
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
October 17, 2023
Via
Benzinga
Crude Oil Moves Lower; Consolidated Communications Shares Jump
October 16, 2023
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
October 16, 2023
Via
Benzinga
Nasdaq Gains 1%; Charles Schwab Earnings Top Views
October 16, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dow Surges Over 200 Points; Empire State Manufacturing Index Falls In October
October 16, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 16, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.